Aims and objectives
This study aims to provide evidence for improving the short-term benefit for advanced cancer patients by relieving the symptoms caused by constipation. As a result, further reduce the usage of medications, and lower the side effects due to medications.
Study design
A single-center, double-blinded, randomized controlled trial study will be conducted at Kaohsiung Chang Gung Memorial Hospital (KCGMH) between March 2020 and February 2022. Participants will be enrolled from the hospice unit at KCGMH. Participants met the inclusion criteria and provide written informed consent will be randomly assigned to experimental group (laser acupuncture [LA]) and control group (sham laser acupuncture [SLA]) in 1:1 ratio. Experimental group will be treated by laser acupuncture, while the control group will receive laser acupuncture without laser output. Participants in both groups will receive conventional treatments such as laxatives, which are evaluated and managed by their hospice physicians. All participants will receive laser acupuncture or sham laser acupuncture once a day for consecutive six days after enrollment.
The study design has been written in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines [30, 31]. The overall schematic chart and study schedule are shown in figures 1 and 2, respectively.
Patient involvement
Patients and their family were involved in the design and conduct of this trial. During the planning of this trial, priority of patient’s needs, introduction of laser acupuncture, choice of outcome measures, methods of recruitment, and dissemination plans of this study were informed by discussions with patients and their family through interviews and group-based patient education.
Participants
The information of the trial will be provided by hospice physician. Participants’ eligibility in the study is assessed by hospice physicians at KCGMH. All participants will provide written consent after receiving an oral explanation of the objectives and procedures of the study by their hospice physicians. All participants with constipation are managed by the hospice physicians’ expertise who have no information about the allocation results.
Inclusion criteria
Subjects are eligible to participate if they meeting all of the following criteria: (1) age of 20 years or older; (2) conscious clear and able to communicate; (3) principal diagnosis of advanced cancer ; (4) diagnosis of constipation by the hospice medical team; (5) treated with laxatives for at least 1 week but still have symptoms of constipation; (6) consent to participate in the study.
Exclusion criteria
Subjects will be excluded if they meet any of the following criteria: (1) unconscious or delirium; (2) intestinal obstruction; (3) active gastrointestinal bleeding; (4) active intraabdominal infection; (5) local skin infection on the acupoints or limb amputee.
Dropout criteria
Participants will be dropped from the trial under the following conditions: (1) unstable vital signs and in need of first aid during study period; (2) the clinical conditions are deteriorated and determined unsuitable to continue this study by medical staff; (3) participants can decide to withdraw from the trial at any time.
Recruitment strategies
The main recruiting way is the inpatients from the hospice unit of KCGMH. Hospice physicians provide the information of this study to participants and then assess the participants’ eligibility to participate in the study.
Blind and randomization
All the participants are informed that they will receive laser acupuncture in addition to the conventional treatment and assess the efficacy of laser acupuncture. The device appearance of laser acupuncture is the same in both LA and SLA groups, except energy output. The participants are unable to recognize whether they are being treated or not, because the laser acupuncture is a low-intensity and non-thermal laser irradiation. Participants will be randomly allocated to LA or SLA group in a 1 : 1 ratio using computer-generated random numbers. Randomization will be performed by an independent researcher who is not involved in the inclusion or exclusion process, treatment and assessment procedures. The trial participants, outcome assessors, and data analysts will be blinded after assignment to interventions using label A and B for the 2 groups till the trial completed. After completing the intervention period, the participants can be allowed to know which group they are assigned to if they want.
Intervention
All participants will still receive conventional treatment depended on hospice physicians’ expertise. The participants in each group will undergo real LA or sham LA treatment once a day for six consecutive days, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies [B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz]; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany).
Acupoints and manipulations are the same in both the experimental and the control groups. The participants in the control group will receive sham laser acupuncture treatment, without any laser output, while the participants in the experimental group will sequentially receive 0.375J of energy at each of the following acupoints: LI4 (Hegu, B3), LI11 (Quchi,B2), PC6 (Neiguan, B3), ST36 (Zusanli, B2), ST37 (Shangjuxu, B2), ST39 (Xiajuxu, B2), SP4 (Gongsun, B3), SP9 (Yinlingquan, B2). The laser treatment will be applied to each point for 5 seconds, to deliver a total treatment dose of 4.5J/cm2. All acupoints are selected and localized according to the WHO Standardized Acupuncture Point Location guidelines [28]. In all the subjects, the laser application will be performed by the same experienced physician who has sufficient training and is a licensed Chinese medicine practitioner in Taiwan. Protective goggle and laser shield are used by the operator and the patient to inhibit visual perception during laser acupuncture. Although LA therapy is noninvasive, in order to improve adherence to intervention, we will explain in detail the indications and advantages of LA and establish a good relationship with patients.
Outcomes measurements
During the trial, participants will record in daily diaries the complete spontaneous bowel movements (CSBMs), symptoms of constipation and change of the diet and exercise. Spontaneous bowel movement (SBM) is defined as a stool not induced by rescue medication, whereas a CSBM is defined as an SBM associated with a sensation of complete evacuation.
Primary outcome
The primary outcome is the number of CSBMs in the past one week. The data will be recorded at baseline and at day 7 after treatment.
Secondary outcome
The secondary outcomes are symptoms of constipation, comfort levels during defecation, and colonic motility. These outcomes will be assessed at the baseline, day 1, day 3, day 5, and day 7.
For the symptoms of constipation, we use five items measurement based on a previously published study [5], including straining during defecation, abdominal pain during defecation, hard stools, sensation of incomplete evacuation, and sensation of anorectal obstruction or blockage. Each item is rated on a four-point Likert scale that ranges from 1-4 points, which a higher score indicates more severe symptom. The comfort level during defecation will be estimated using a 10-cm visual analogue scale with points of 0-10 points, with a higher score indicates a higher level of discomfort during defecation. The frequency of colonic motility in times per minute will be measured by auscultation of the lower right abdomen with a stethoscope.
Sample size calculation
There is lacking previous study of laser acupuncture for the treatment of constipation in patients with advance cancer. Determination of the necessary sample size is based on a previous study of the effects of electroacupuncture for functional constipation [29]. The mean ± standard deviation of constipation symptom score at week 2 was 6.81 ± 2.62 in acupuncture group and 8.44 ± 2.61 in control group. Anticipating a power of 95% (1-β=0.95), statistical significance (α=0.05) of 95% and a dropout rate of 10%, a total of 74 participants is required using G*power analysis in this study.
Statistical analysis
The data of the participants who complete the 6-day intervention will be expressed as frequencies, percentages or mean ± standard deviation. The differences between the LA and SLA groups are compared using the chi-square test or t-test. Analysis of covariance will be used to examine the differences on symptoms of constipation, comfort levels during defecation, and colonic motility between the LA and SLA groups, adjusted for their respective baseline levels. Differences are considered to be significant at a p value of <.05. All analyses will be performed by using the IBM SPSS Statistics package version 24.0 (SPSS Inc., Chicago, IL, USA). The missing data of participants who do not complete the 6-day intervention will be excluded in the analysis.
Adverse events monitoring
Data monitoring committee (DMC) is not needed because laser acupuncture is general practice and noninvasive intervention. Nevertheless, the adverse reactions such as diarrhea, abdominal pain, fainting during laser acupuncture treatment will be monitored during the trial period. Any suspected adverse events will be reported by the patients’ hospice physicians to the researcher. Adverse events will be managed by the patient’s hospice physician, and other specialist doctors will be consulted if necessary. The researchers have the right to terminate the trial if any severe adverse events are noted. Independent audits are performed by the Institutional Review Board of the Chang Gung Medical Foundation every six months.
Privacy and Confidentiality
There will be a study code that represents the identity of patient. This code will not show patient’s name, identity card number, and address. For the results and diagnosis of participants’ visit, the study investigators will maintain a confidential attitude and be careful to maintain their privacy. If the investigators publish the results, patient’s identity will remain confidential.